Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 in Advanced Melanoma
NCT06214156Phase 2Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of MVR-T3011 in melanoma, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jan 2024; status: recruiting.
02
Drugs
MVR-T3011
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06214156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214156.